zurück Home

Immuntherapie des NSCLC

Allgemeines

  
Pembrolizumab Pembrolizumab in Kombination mit
Pemetrexed und
Carboplatin (US-Zulassung)
  • NSCLC
  • nicht-SCC
  • metastasiert
  • First - Line
Pembrolizumab-Monotherapie
  • NSCLC
  • metastasiert
  • First - Line
  • PD-L1 > 50%
  • nicht EGFR-Mutation
  • nicht ALK-positiv
G-BA 8/2018: beträchtlicher Zusatznutzen

first-line Studien

 First-Line randomiierte Studien mit PD-1/PD-L1 Inhibitoren beim NSCLC
Studie Population Design Primärer Endpunkt ClinicalTrials.gov Identifier
CheckMate 026 PD-L1 – positives NSCLC Nivolumab v platinum doublet Chemotherapie PFS* NCT02041533
CheckMate 227 PD-L1 – positives and PD-L1 – negative NSCLC Kohorten PD-L1 – positive Kohorte: nivolumab v nivolumab- ipilimumab v platinum doublet Chemotherapie OS, PFS NNCT02477826
PD-L1 – negative Kohorte: nivolumab-ipilimumab v nivolumab plus platinum doublet v platinum doublet Chemotherapie
KEYNOTE 024 PPD-L1 – positives NSCLC Pembrolizumab v platinum doublet Chemotherapie PFS NCT02142738
KEYNOTE 042 PPD-L1 – positives NSCLC Pembrolizumab v platinum doublet Chemotherapie OS NCT02220894
KEYNOTE 189 Nonsquamous NSCLC Platinum-pemetrexed with or without pembrolizumab PFS NCT02578680
IMpower 110 PPD-L1 – positives nonsquamous NSCLC Atezolizumab v platinum-pemetrexed PFS NCT02409342
IMpower 111 PPD-L1 – positives squamous NSCLC Atezolizumab v platinum-gemcitabine PFS NCT02409355
IMpower 130 Nonsquamous NSCLC Atezolizumab, carboplatin, and NAB-paclitaxel v carboplatin and NAB-paclitaxel PFS NCT02367781
IMpower 131 Squamous NSCLC Atezolizumab, carboplatin, and NAB-paclitaxel v atezolizumab, carboplatin, and paclitaxel v carboplatin and NAB-paclitaxel PFS NCT02367794
IMpower 150 Nonsquamous NSCLC Atezolizumab, carboplatin, and paclitaxel with or without bevacizumab v carboplatin, paclitaxel, and bevacizumab PFS NCT02366143
MYSTIC NNSCLC Durvalumab v durvalumab-tremelimumab v platinum doublet Chemotherapie PFS NCT02453282
NEPTUNE NNSCLC Durvalumab-tremelimumab v platinum doublet Chemotherapie OS NCT02542293

Teil von

 Therapie des NSCLC NSCLC Tumoren des Thorax Onkologie

Quellen

 1.) Brahmer J, Reckamp KL, Baas P, et al.:
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer.
N Engl J Med 2015;373:123-135

2.) Borghaei H, Paz-Ares L, Horn L, et al.:
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.
N Engl J Med 2015;373:1627-1639

3.) Herbst RS, Baas P, Kim DW, et al.:
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial.
Lancet 2016;387:1540-1550
4.) Fehrenbacher L, Spira A, Ballinger M, et al.:
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial.
Lancet 2016;387:1837-1846

5.) Thatcher N, Hirsch FR, Luft AV, et al.:
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): An open-label, randomised, controlled phase 3 trial.
Lancet Oncol 2015;16:763-774

6.) Gettinger S, Rizvi NA, Chow LQ, et al.:
Nivolumab monotherapy for fi rst-line treatment of advanced non – small-cell lung cancer.
J Clin Oncol 2016;34:2980-2987

7.) Rizvi NA, Hellmann MD, Brahmer JR, et al.:
Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non – small-cell lung cancer.
J Clin Oncol 2016;34:2969-2979

8.) Papadimitrakopoulou V, Patnaik A, Borghaei H, et al.:
Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohorts A and C.
J Clin Oncol 2015;33 Suppl: Abstr 8031

wichtiger Hinweis! Für die Richtigkeit von Indikationen, Dosisangaben und Zielvolumina kann keine Garantie übernommen werden.
In Zweifelsfällen sind die aktuellen nationalen und internationalen Leitlinien einzusehen oder der Hersteller zu kontaktieren.
blauer Punkt

Impressum                               Zuletzt geändert am 22.04.2026 16:13